Thrive Capital Management (Pennsylvania)’s iShares Biotechnology ETF IBB Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,538	Closed	-$515K	–	126
2024 Q3	$515K	Sell	3,538 -68	-2%	-$9.84K	0.24%	121
2024 Q2	$495K	Buy	+3,606	New	+$481K	0.23%	125
2024 Q1	–	Sell	-14,231	Closed	-$1.93M	–	155
2023 Q4	$1.93M	Sell	14,231 -1,326	-9%	-$162K	1.03%	32
2023 Q3	$1.9M	Buy	15,557 +2,693	+21%	+$342K	1.05%	29
2023 Q2	$1.63M	Sell	12,864 -245	-2%	-$31.8K	0.93%	33
2023 Q1	$1.67M	Sell	13,109 -611	-4%	-$80K	1.05%	27
2022 Q4	$1.8M	Sell	13,720 -1,475	-10%	-$191K	1.18%	21
2022 Q3	$1.78M	Sell	15,195 -806	-5%	-$100K	1.2%	20
2022 Q2	$1.88M	Sell	16,001 -97	-0.6%	-$11.5K	1.3%	20
2022 Q1	$2.1M	Buy	16,098 +6,195	+63%	+$807K	1.27%	23
2021 Q4	$1.51M	Buy	+9,903	New	+$1.53M	0.98%	25

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s IBB Position: Q4 2024 in Review

Thrive Capital Management (Pennsylvania) sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 3,538 shares — an estimated $515K sold.

Thrive Capital Management (Pennsylvania) first reported a position in IBB in Q4 2021 and held it in 11 quarters. The position peaked at $2.1M in Q1 2022. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

Thrive Capital Management (Pennsylvania) reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
Thrive Capital Management (Pennsylvania) sold 3,538 iShares Biotechnology ETF shares in Q4 2024, an estimated $515K.
Thrive Capital Management (Pennsylvania) first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 11 quarters.
Thrive Capital Management (Pennsylvania)'s iShares Biotechnology ETF position peaked at $2.1M in Q1 2022.
874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q4 2024, filed 13 Feb 2025.